EARNINGS PREVIEW: AstraZeneca 2Q Seen Strong, 2H To Get Tough

26th Jul 2010 16:27

AstraZeneca PLC (AZN): 2Q Due: July 29 at 0600 GMT DJ Survey of 10 Analysts Average Net Profit: $1.94Bln, up 13% ($1.71Bln in 2Q 2009) Average Sales 2Q 2010: $8.03Bln, up 1% ($7.96Bln in 2Q 2009) Note: Evolution Securities says AstraZeneca looks set to release strong 2Q results helped by limited competition for drugs Toprol XL and Zoladex in Europe and from strength of dollar, in which it reports. Adds, the second half will be difficult, though, reflecting generic competition for drugs Merrem and Arimidex. Thursday's data will be overshadowed by an FDA advisory panel decision on new blood clot preventer Brilinta on July 28. Has sell on stock. Shares -0.8% at 3,122p. ([email protected]) Call Us In London: 44-20-7842-9464 E-mail: [email protected] (END) Dow Jones Newswires July 26, 2010 11:27 ET (15:27 GMT)